Isingeniso
I-Tirzepatide, eyakhiwe ngu-Eli Lilly, iyinoveli yomuthi we-peptide omele ingqophamlando ekwelapheni uhlobo 2 lwesifo sikashukela kanye nokukhuluphala. Ngokungafani nama-agonists endabuko e-GLP-1 (glucagon-like peptide-1), i-Tirzepatide isebenzakokubili i-GIP (i-insulinotropic polypeptide encike kuglucose)futhiI-GLP-1 receptors, ithole igama elithi aI-agonist ye-receptor embili. Le ndlela embaxambili inika amandla amandla aphezulu ekulawuleni ushukela wegazi kanye nokunciphisa isisindo somzimba, ikakhulukazi ezigulini ezinesifo sikashukela sohlobo 2 kanye nokukhuluphala.
Indlela Yokwenza
-
GIP receptor activation: Ithuthukisa ukukhiqizwa kwe-insulin futhi ithuthukise ukubekezelela ushukela.
-
Ukusebenza kwe-GLP-1 receptor: Ikhuthaza ukukhishwa kwe-insulin, icindezela ukukhiqizwa kweglucagon, futhi ibambezele ukuphuma kwesisu.
-
I-synergy ekabili: Inikeza ukulawulwa okusebenzayo kwe-glycemic kanye nokunciphisa isisindo okubalulekile.
Ukuhlaziywa Kwedatha Yomtholampilo
1. Izilingo ezedlula zonke (Uhlobo 2 Lwesifo sikashukela)
Ngaphakathi kokuningiSURPASS izivivinyo zomtholampilo, i-Tirzepatide iphumelele i-insulin ne-Semaglutide emiphumeleni yokunciphisa i-glycemic nesisindo.
| Iqembu Leziguli | Umthamo | Isilinganiso. Ukwehliswa kwe-HbA1c | Isilinganiso. Ukwehla Kwesisindo |
|---|---|---|---|
| Isifo sikashukela sohlobo 2 | 5 mg | -2.0% | -7.0 kg |
| Isifo sikashukela sohlobo 2 | 10 mg | -2.2% | - 9.5 kg |
| Isifo sikashukela sohlobo 2 | 15 mg | -2.4% | - 11.0 kg |
➡ Uma kuqhathaniswa ne-Semaglutide (1 mg: HbA1c -1.9%, Isisindo -6.0 kg), i-Tirzepatide ibonise imiphumela ephakeme kokubili ukulawulwa kwe-glycemic nokulahlekelwa isisindo.
2. SURMOUNT Trials (Ukukhuluphala)
Ezigulini ezikhuluphele ezingenaso isifo sikashukela, i-Tirzepatide ibonise ukusebenza kahle kokuncipha kwesisindo okumangazayo.
| Umthamo | Isilinganiso. Ukunciphisa Isisindo (amaviki angu-72) |
|---|---|
| 5 mg | -15% |
| 10 mg | -20% |
| 15 mg | -22.5% |
➡ Esigulini esinesisindo esingu-100 kg, umthamo omkhulu we-Tirzepatide ungathola ukuncipha kwesisindo esizungezile.22.5 kg.
Izinzuzo Eziyinhloko
-
Indlela ekabili: Ngaphandle kwama-agonists angashadile e-GLP-1.
-
Ukusebenza okuphezulu: Isebenza kahle kukho kokubili ukulawulwa kwe-glycemic nokuphathwa kwesisindo.
-
Ukusebenza okubanzi: Ifanele kokubili isifo sikashukela kanye nokukhuluphala.
-
Amandla emakethe aphezulu: Isidingo esikhulayo sezikhundla zokwelapha ukukhuluphala i-Tirzepatide njengesidakamizwa se-blockbuster esizayo.
I-Market Outlook
-
Isibikezelo sosayizi wemakethe: Ngo-2030, imakethe yezidakamizwa ye-GLP-1 yomhlaba wonke kulindeleke ukuthi idluleI-USD 150 billion, kanti i-Tirzepatide cishe izothatha isabelo esivelele.
-
Isimo sokuncintisana: Imbangi enkulu yi-Semaglutide kaNovo Nordisk (Ozempic, Wegovy).
-
Inzuzo: Idatha yomtholampilo ibonisa i-Tirzepatide inikeza ukulahlekelwa kwesisindo esiphakeme uma kuqhathaniswa ne-Semaglutide, iqinisa ukuncintisana kwayo kwemakethe ekwelapheni ukukhuluphala.
Isikhathi sokuthumela: Sep-12-2025